Pharma Equity Group AS (OCSE:PEG) LT-Debt-to-Total-Asset: 0.12 (As of Dec. 2025)


What is Pharma Equity Group AS LT-Debt-to-Total-Asset?

Pharma Equity Group AS OCSE:PEG -3.89% LT-Debt-to-Total-Asset is 0.12 as of Dec. 2025. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pharma Equity Group AS's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.12.

Pharma Equity Group AS's long-term debt to total assets ratio declined from Dec. 2024 (0.16) to Dec. 2025 (0.12). It may suggest that Pharma Equity Group AS is progressively becoming less dependent on debt to grow their business.

Pharma Equity Group AS  (OCSE:PEG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pharma Equity Group AS LT-Debt-to-Total-Asset Related Terms

Pharma Equity Group AS LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS LT-Debt-to-Total-Asset Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.00 0.12 0.16 0.12

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.24 0.16 0.25 0.12

Pharma Equity Group AS LT-Debt-to-Total-Asset Calculation

Pharma Equity Group AS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=4.598/38.898
=

Pharma Equity Group AS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=4.598/38.898
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.12 mean?
Pharma Equity Group AS (OCSE:PEG) has a LT-Debt-to-Total-Asset of 0.12 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pharma Equity Group AS and its competitors.
Is Pharma Equity Group AS's LT-Debt-to-Total-Asset too high?
Pharma Equity Group AS's current LT-Debt-to-Total-Asset is 0.12.
How does Pharma Equity Group AS's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Pharma Equity Group AS's LT-Debt-to-Total-Asset of 0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pharma Equity Group AS and its competitors. Pharma Equity Group AS's current LT-Debt-to-Total-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current LT-Debt-to-Total-Asset of 0.12. The current LT-Debt-to-Total-Asset is 0.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current LT-Debt-to-Total-Asset is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .